Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Lowers Price Target to $290

Benzinga Newsdesk www.benzinga.com Neutral 82.2%

Neg 0% Neu 82.2% Pos 0%

Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and lowers the price target from $320 to $290.